Skip to main content
. Author manuscript; available in PMC: 2016 Apr 18.
Published in final edited form as: Br J Haematol. 2011 Aug 18;155(2):182–189. doi: 10.1111/j.1365-2141.2011.08831.x

Table V.

Adverse Events

Adverse event (CTCAEv3)
Gr 3 #(%)
Gr 4 #(%)
Skin 5 (10%) 0
Hepatic transaminases 5 (10%) 3 (6%)
Pulmonary 18 (36%) 5 (10%)
Infection 12 (24%) 8 (16%)
Gastrointestinal 6 (12%) 0
Hyperbilirubinaemia 3 (6%) 1 (2%)
Renal 2 (4%) 0
Pain 1 (2%) 0
Neuropathy 1 (2%) 0
Tumour lysis 1 (2%) 0

CTCAEv3, Common Terminology Criteria for Adverse Events v3.0